- Home
- MXCT vs PVLA Comparison
MXCT vs PVLA Comparison
Compare MXCT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- PVLA
- Stock Information
- Founded
- MXCT 1999
- PVLA 2015
- Country
- MXCT United States
- PVLA United States
- Employees
- MXCT N/A
- PVLA N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- PVLA Health Care
- Exchange
- MXCT Nasdaq
- PVLA Nasdaq
- Market Cap
- MXCT 242.4M
- PVLA 285.2M
- IPO Year
- MXCT 2021
- PVLA N/A
- Fundamental
- Price
- MXCT $2.04
- PVLA $36.55
- Analyst Decision
- MXCT Strong Buy
- PVLA Strong Buy
- Analyst Count
- MXCT 2
- PVLA 8
- Target Price
- MXCT $7.50
- PVLA $47.50
- AVG Volume (30 Days)
- MXCT 473.0K
- PVLA 176.8K
- Earning Date
- MXCT 08-06-2025
- PVLA 08-15-2025
- Dividend Yield
- MXCT N/A
- PVLA N/A
- EPS Growth
- MXCT N/A
- PVLA N/A
- EPS
- MXCT N/A
- PVLA N/A
- Revenue
- MXCT $37,675,000.00
- PVLA N/A
- Revenue This Year
- MXCT $8.36
- PVLA N/A
- Revenue Next Year
- MXCT $20.14
- PVLA N/A
- P/E Ratio
- MXCT N/A
- PVLA N/A
- Revenue Growth
- MXCT N/A
- PVLA N/A
- 52 Week Low
- MXCT $1.97
- PVLA $11.17
- 52 Week High
- MXCT $5.20
- PVLA $40.50
- Technical
- Relative Strength Index (RSI)
- MXCT 40.39
- PVLA N/A
- Support Level
- MXCT $2.18
- PVLA N/A
- Resistance Level
- MXCT $2.31
- PVLA N/A
- Average True Range (ATR)
- MXCT 0.11
- PVLA 0.00
- MACD
- MXCT -0.01
- PVLA 0.00
- Stochastic Oscillator
- MXCT 18.52
- PVLA 0.00
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.